Randomised phase 2 trial of SIR-spheres® plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer

Journal of Surgical Oncology

Volumn 88, Issue 2, 2004, Pages 78-85

  Van Hazel, Guy ^a,b   Blackwell, Anthony ^c   Anderson, James ^a   Price, David ^a   Moroz, Paul ^a   Bower, Geoff ^a   Cardaci, Giuseppe ^a   Gray, Bruce ^a,d  

^a Mount Hospital   (Australia)

^b SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^c GREENSLOPES PRIVATE HOSPITAL   (Australia)

^d Sirtex Medical Limited   (Australia)

Author keywords

Colorectal cancer; Liver metastases; SIR Spheres ; SIRT

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL; FOLINIC ACID; MICROSPHERE; NARCOTIC ANALGESIC AGENT; YTTRIUM 90;

ABDOMINAL PAIN; ABSCESS DRAINAGE; ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DRUG DELIVERY SYSTEM; FEMALE; GASTRITIS; GRANULOCYTOPENIA; HEPATIC ARTERY; HUMAN; LIVER ABSCESS; LIVER CIRRHOSIS; LIVER METASTASIS; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RADIATION DOSE; SELECTIVE INTERNAL RADIATION THERAPY; SEPSIS; TREATMENT OUTCOME; VOMITING; COLORECTAL TUMOR; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; LIVER TUMOR; METASTASIS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; LIVER NEOPLASMS; MALE; MICROSPHERES; MIDDLE AGED; QUALITY OF LIFE; RADIOTHERAPY DOSAGE; SURVIVAL RATE;

EID: 7944226700     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/jso.20141     Document Type: Article

References (30)

1. Gilbert J, Jeffery I, Evans M, et al.: Sites of recurrent tumour after curative colorectal surgery. Implications for adjuvant therapy. Br J Surg 1984;71:203-205.
2. Chamberlain M, Gray BN, Heggie JCP, et al.: Hepatic metastases: A physiological approach to treatment. Br J Surg 1983;70:596-598.
3. Burton MA, Gray BN, Klemp P, et al.: Selective internal radiation therapy: Distribution of radiation in the liver. Eur J Cancer Clin Oncol 1989;25:1487-1491.
4. Fox RA, Klemp PFB, Egan G, et al.: Dose distribution following selective internal radiation therapy. Int J Rad Oncol Biol Phys 1991;21:463-467.
5. Ho S, Lau WY, Leung T, et al.: Partition model for estimating radiation doses from yttrium-90 microspheres in treating hepatic tumours. Eur J Nuclear Med 1996;23:947-952.
6. Yorke E, Jackson A, Fox R, et al.: Can current models explain the lack of liver complcations in Y-90 microsphere therapy? Clin Cancer Res 1999;5:3024-3030.
7. Gray BN, Matz L, Burton MA, et al.: Tolerance of the liver to Yttrium-90 irradiation. Int J Rad Oncol Biol Phys 1990;18:619-623.
8. Burton MA, Kelleher DK, Codde JP, et al.: Alteration of experimental liver tumour blood flow. I. Effects of phenylephrine and vasopressin. Cancer J 1990;3:346-350.
9. Burton MA, Gray BN: Redistribution of blood flow in experimental hepatic tumours with nor-adrenaline and propanalol. Br J Cancer 1987;56:585-588.
10. Burton MA, Gray BN, Colletti A: Effect of Angiotensin-2 on blood flow in the transplanted sheep squamous cell carcinoma. Eur J Cancer Clin Oncol 1988;24:1373-1376.
11. Burton M, Gray B, Self G, et al.: Manipulation of experimental rat and rabbit liver tumour blood flow with angiotensin-2. Cancer Res 1985;45:5390-5393.
12. Andrews J, Suzette C, Walker-Andrews R, et al.: Modulation of liver tumour blood flow with hepatic arterial epinephrine: A SPECT study. Radiology 1989;173:645-647.
13. Gray BN, Burton MA, Kelleher D, et al.: Selective internal radiation (SIR) therapy for treatment of liver metastases: Measurement of response rate. Surg Oncol 1989;42:192-196.
14. Gray B, Anderson J, Burton M, et al.: Regression of liver metastases following treatment with yttrium90 microspheres. Aust NZ J Surg 1992;62:105-110.
15. Gray BN, Van Hazel G, Buck M, et al.: Treatment of colorectal liver metastases with SIR-Spheres plus chemotherapy. GI Cancer 2000;3:249-257.
16. Gray BN, Van Hazel G, Anderson J, et al.: Randomised trial of SIR-Spheres plus chemotherapy versus chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Annals Oncol 2001;12:1711-1720.
17. Stubbs R, Cannan R, Mitchell A, et al.: Selective internal radiation therapy (SIRT) with yttrium microspheres for liver tumours (abstract). Hepatogastroenterology 1998;45(Supp 2): LXXVII.
18. Lau W, Leung T, Ho S, et al.: Treatment of inoperable hepatocellular carcinoma with yttrium90 microspheres. A phase 1 and 2 study. Br J Cancer 1994;70:994-999.
19. Lau W, Ho S, Leung T, et al.: Selective internal radiation therapy for non-resectable hepatocellular carcinoma with intraarterial infusion of yttrium90 microspheres. Int J Rad Oncol Biol Phys 1998;40:583-592.
20. Ettinger D, Leitchner P, Siegelman S, et al.: Computed tomography assisted volumetric analysis of primary liver tumour as a measure of response to therapy. Am J Clin Oncol 1985;8:413-418.
21. Therasse P, Arbuck S, Eisenhauer E, et al.: New guidelines to evaluate the response to treatment in solid tumours. J Natl Cancer Inst 2000;92:205-216.
22. Schipper H, Clinch J, McMurray A, et al.: Measuring the quality of life of cancer patients: The functional living index-cancer: Development and validation. J Clin Oncol 1984;2:472-483.
23. Spitzer WO, Dobson AJ, Hall J, et al.: Measuring the quality of life of cancer patients: A concise QL-index for use by physicians. J Chronic Dis 1981;34:585-597.
24. Tibshirani R: A plain man's guide to the proportional hazards model. Clin Invest Med 1982;5:63-68.
25. Archer S, Gray BN: The vascularisation of small liver metastases. Br J Surg 1989;76:545-548.
26. Machover D: A comprehensive review of 5-fluorouracil and leucovorin in patients with metastatic colorectal carcinoma. Cancer 1997;80:1179-1187.
27. Saltz L, Cox J, Blanke C, et al.: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000;343:905-914.
28. Pitot H, Wender D, O'Connell M, et al.: Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. J Clin Oncol 1997;15:2910-2919.
29. Diaz-Rubio E, Sastre J, Zaniboni A, et al.: Oxaliplatin as single agent in previously untreated colorectal carcinoma: A phase II multicentric study. Ann Oncol 1998;9:105-108.
30. Machover D, Diaz-Rubio E, de Gramont A, et al.: Two consecutive phase II studies with oxaliplatin for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 1996;7:95-98.